Outcome of Board Meeting held today for results for the Financial Year ended March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Deccan Health Care's Board approved Standalone and Consolidated Audited Financial Results for FY25 with an Unmodified (clean) opinion from statutory auditor Keyur Shah & Associates. Standalone revenue from operations grew ~25.8% YoY to Rs 7,513.19 lakhs (vs Rs 5,972.89 lakhs in FY24), but Profit After Tax declined ~21.3% to Rs 119.79 lakhs (vs Rs 152.17 lakhs) due to higher material and operating costs. Q4 FY25 saw standalone revenue jump ~30% YoY to Rs 2,082.12 lakhs, with a modest PAT of Rs 13.60 lakhs. Consolidated PAT fell to Rs 115.87 lakhs from Rs 149.26 lakhs. The company also appointed M/s M R Bhatia and Co as Secretarial Auditors for FY26 and raised Rs 331.80 lakhs via share warrant conversions during the quarter.
Mixed signals for shareholders: strong top-line growth but margin compression and PAT decline raise profitability concerns. Negative operating cash flow (Rs -660 lakhs standalone) remains a watchpoint, though improving from prior year. Clean audit opinion and zero investor complaints are positives; expect cautious near-term stock reaction given weak bottom-line.